− HEALTH Agentic artificial intelligence (AI) is an emerging development in the digital transformation of healthcare.…− HEALTH Artificial intelligence (AI) is expanding the capacity of public health systems to detect infectious disease…+ HEALTH Purpose To estimate diagnostic performance of a deep learning algorithm for extremity fracture detection on r…− HEALTH Objective Hypomimia, or reduced facial expressiveness, is a cardinal motor feature of Parkinson's disease (PD…− SCIENCE Background Generative artificial intelligence (GenAI) chatbots have shown utility in assisting with various r…− HEALTH ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor recep…− HEALTH Her name was June. June would be the last month she ever knew. I remember the way her bed made her so small,…− LIFESTYLE Precision nutrition on a global scale necessitates an understanding of food not as static collections of so-c…
TruaceTracing the truth around AIWednesday, September 23, 2026
Subscribe
Health·P Space·Evidence-backed problem·Published 2026-09-23

AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems

Abstract: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision…

TRV-2026-1173Peer-reviewedPermanent record — cite & verify
AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems

Small cell carcinoma - CT scan (6327961286) by Yale Rosen from USA. CC BY-SA 2.0 · https://creativecommons.org/licenses/by-sa/2.0

The quick read

ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.

Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.

Main points
  • We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.
  • Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation.
  • AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
Problem

ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup).

Sources

Reader signal

How should this claim be treated?

The debate